Novo Nordisk’s Ozempic meets primary endpoint in Sustain 9 diabetes trial

Image: Novo Nordisk’s Ozempic succeeds in SUSTAIN 9 diabetes trial. Photo: courtesy of Novo Nordisk A/S.